Clinical trials: B-cell Leukemia
Anemia, Leukemia
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00661999
- Testing
- darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose
- Where
- 2 sites in United States
- Volunteers
- 502 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, CLL / SLL
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
A non-myeloablative treatment strategy and uniform selection criteria will enable patients with a variety of low grade B-Cell malignancies to attain long term disease control without unacceptably high treatment related mortality.
- Conditions
- Multiple Myeloma, CLL / SLL, Non Hodgkin's Lymphoma, Waldenstroms
- Trial name
- NCT00714259
- Testing
- Fludarabine, Total Body Irradiation, Infusion of Stem Cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
B-Cell Chronic Lymphocytic Leukemia
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
This is a Phase 3, prospective, multicenter, open-label, randomized, controlled study to evaluate and compare the efficacy and safety of fludarabine plus alemtuzumab versus fludarabine alone as second-line therapy for patients…
- Trial name
- NCT00086580
- Testing
- FluCAM [Fludara + Campath], fludarabine phosphate
- Where
- 48 sites in United States, Austria and 13 more
- Volunteers
- 335 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma, Leukemia
Cellular Therapy With Cord Blood Cells
The goal of this clinical research study is to learn if giving umbilical cord blood along with standard stem cells after high-dose chemotherapy will improve the response to a stem cell transplant.
- Conditions
- Multiple Myeloma, Leukemia, Lymphoma
- Trial name
- NCT00427557
- Testing
- Fludarabine, Melphalan, Umbilical Cord Blood
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB)…
- Conditions
- Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- UCBT (NCT01930162)
- Testing
- HSC835
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow.
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia
- Trial name
- NCT03480360
- Testing
- Cyclophosphamide, Fludarabine, Total Body Irradiation
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Chronic Lymphocytic Leukemia
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and mitoxantrone plus rituximab, with the growth factor pegylated filgrastim, will improve the response to treatment…
- Trial name
- NCT00254410
- Testing
- Fludarabine, Cyclophosphamide, Mitoxantrone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.
- Trial name
- NCT00560794
- Testing
- Blinatumomab (MT103)
- Where
- 6 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Amgen Research (Munich) GmbH
Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with untreated acute lymphoblastic leukemia.
- Conditions
- Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, L1 Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00061945
- Testing
- allopurinol, cyclophosphamide, daunorubicin hydrochloride
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukaemia
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
This study will assess the efficacy (response rate) of oral lenalidomide in the treatment of patients with symptomatic, previously untreated, chronic lymphocytic leukemia (CLL), toxicity of lenalidomide in patients with CLL as…
- Trial name
- Rev-CLL (NCT00751296)
- Testing
- Lenalidomide
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University Health Network, Toronto
B-cell Acute Lymphoblastic Leukemia
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
- Trial name
- BLAST (NCT01207388)
- Testing
- Blinatumomab
- Where
- 75 sites in Austria, Belgium and 9 more
- Volunteers
- 116 people
- Sponsor
- Amgen Research (Munich) GmbH
Follicular Lymphoma, Marginal Zone Lymphoma
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and works in two different ways. It affects the development of new cancer cells by blocking two enzymes that cancer cells need to reproduce.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00644189
- Testing
- Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Graft vs Host Disease, Myelodysplastic Syndromes
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donors T lymphocytes have undergone "selective depletion." Certain patients with cancers of the blood undergo transplantation of…
- Conditions
- Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Leukemia, Myeloid
- Trial name
- NCT00025662
- Testing
- RFT5-SMPT-dgA, Isolex system
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Background: Chronic lymphocytic leukemia and small lymphocytic lymphoma (hereby referred as CLL) are tumors of B cells. A subset of patients categorized as high-risk CLL has a poor clinical outcome when treated with conventional…
- Conditions
- B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Chronic Lymphatic
- Trial name
- NCT03204188
- Testing
- Ibrutinib, Fludarabine, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine (investigational therapy) for the prevention of a complication of bone marrow transplantation known…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00975975
- Testing
- Basiliximab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indiana University
Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
This phase II trial studies how well ibrutinib works in treating patients with B-cell acute lymphoblastic leukemia that has come back after treatment or has not responded to other treatment.
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT02129062
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Primary Objective: To evaluate the efficacy (combined morphologic and flow remissions) of a combination of fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL.
- Trial name
- NCT00794820
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
RATIONALE: An Opioid Titration Order Sheet that allows healthcare providers to adjust the dose and schedule of pain medication may help improve pain treatment for patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00666211
- Testing
- educational intervention, Titrated pain management, questionnaire administration
- Where
- 11 sites in United States
- Volunteers
- 98 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
This randomized phase III trial is studying tacrolimus, methotrexate, and sirolimus to see how well they work compared to tacrolimus and methotrexate in preventing graft-versus-host disease in young patients who are undergoing…
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00382109
- Testing
- thiotepa, cyclophosphamide, tacrolimus
- Where
- 50 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Children's Oncology Group